Intended for UK Healthcare Professionals FICTIONAL DRUG - FOR DEMONSTRATION PURPOSES ONLY

The first IL-47 blocker for moderate-to-severe allergic rhinitis

Targeting the root cause of allergic inflammation.

DEMOZUMAB is indicated for add-on maintenance treatment of moderate-to-severe allergic rhinitis in adults and adolescents 12 years and older whose disease is inadequately controlled.3
DEMOZUMAB patient imagery

Introducing SPRING-1

A Phase III, randomised, double-blind, placebo-controlled trial evaluating DEMOZUMAB in 782 adults and adolescents with moderate-to-severe allergic rhinitis inadequately controlled on standard therapy.1

Primary Endpoint Results

Mean change from baseline in daily Total Nasal Symptom Score (TNSS) averaged over Weeks 12-24.

-2.84
vs -0.87 placebo (p<0.001)1

DEMOZUMAB demonstrated statistically significant and clinically meaningful improvements in nasal symptoms compared to placebo when added to standard therapy.

View study details →

About DEMOZUMAB

Add-on therapy for patients inadequately controlled on intranasal corticosteroids.1,3

Efficacy data

Statistically significant improvement in Total Nasal Symptom Score versus placebo when added to intranasal corticosteroids in the SPRING-1 trial.1

See efficacy data

Mechanism of action

Monoclonal antibody that selectively blocks IL-47, an upstream cytokine involved in type 2 inflammation.2

Understand MOA

Dosing and administration

300 mg administered by subcutaneous injection once every 4 weeks.3 Pre-filled auto-injector available for at-home administration.

View dosing guide

Ready to learn more?

Access prescribing information, clinical trial data, and patient resources.

View prescribing information

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to Siguru Limited via the Siguru Reporting Tool or on 0800 987 6543.

If you are from outside the UK, you can report adverse events to Siguru Limited by selecting your region and market here.

References

  1. Mitchell PD, et al. Efficacy and safety of vigilanafine in adults and adolescents with moderate-to-severe allergic rhinitis: Results from the SPRING-1 randomised controlled trial. J Allergy Clin Immunol. 2025;155(3):687-696.
  2. Zhang H, Rahman S. IL-47 blockade in allergic disease: Mechanisms and therapeutic implications. Nat Rev Immunol. 2024;24(9):623-638.
  3. DEMOZUMAB (vigilanafine) Summary of Product Characteristics. Siguru Limited. December 2025.

UK-DMB-2025-012 | Date of preparation: December 2025